Inmune Bio INMB
NASDAQ INMB
$1.61 +0.01 (+0.62%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inmune Bio (INMB) Total Non-Current Liabilities (2021 - 2023)

Updated

Inmune Bio (INMB) reported Total Non-Current Liabilities of $17.96 million for Q3 2023.

Analysis

Inmune Bio (INMB) Total Non-Current Liabilities (2021 - 2023) Analysis & Trends

At the end of FY2022, Inmune Bio posted Total Non-Current Liabilities of $21.14 million, up 7.2% from FY2021.

  • By year, Total Non-Current Liabilities came in at $19.72 million in FY2021.
  • The Q3 2023 figure ranks as the lowest quarterly Total Non-Current Liabilities since Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 60.66 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 105.50 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 106.45 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 80.25 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 48.34 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.91 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 78.66 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 35.10 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 97.04 Bn
10 Inmune Bio 42.88 Mn -49.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 17.96 Mn
Dec 31, 2022 21.14 Mn
Mar 31, 2022 18.71 Mn
Dec 31, 2021 19.72 Mn
Sep 30, 2021 19.17 Mn
Jun 30, 2021 17.31 Mn
API Access

Inmune Bio Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=INMB&period=max&api_key=YOUR_API_KEY